CAR-engineered NK cells: “Breakthrough to Lead the Fight Against Cancers”
Cancer immunotherapy – therapies that harness the power of a patient’s immune system to fight their disease – had officially arrived.
Fast-forward three years and now many pharma companies are racing to get FDA approval tripping over themselves trying to discover new ways to capitalize CAR-T drugs on the promise of immunotherapy.
Our research main focus on CAR-engineered NK cells for solid tumor. Because Adoptive cell therapy has received a great deal of interest in the treatment of advanced cancers that are resistant to traditional therapy. The tremendous success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells in the treatment of cancer, especially hematological cancers, has exposed CAR’s potential. However, the toxicity and significant limitations of CAR-T cell immunotherapy prompted research into other immune cells as potential candidates for CAR engineering. NK cells are a major component of the innate immune system, especially for tumor immunosurveillance. They have a higher propensity for immunotherapy in hematologic malignancies because they can detect and eliminate cancerous cells more effectively.
Extensive preclinical research has shown that NK cells can be effectively engineered to express CARs with substantial cytotoxic activity against both hematological and solid tumors, establishing evidence for potential clinical trials of CAR-NK cells. We discuss recent advances in CAR-NK cell engineering in a variety of hematological malignancies, as well as the main challenges that influence the outcomes of CAR-NK cell-based tumor immunotherapies.
Click the below web link to know more about the CAR-NK engineered Immunotherapy for solid tumors https://doi.org/10.1186/s13287-021-02462-y